Our Science
Pipeline
A new class of antifungal. Powerful. Different.
Ibrexafungerp is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
At SCYNEXIS, we believe that ibrexafungerp could be essential therapy in the treatment of multiple serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and more. Learn more about our pipeline below.
Community Infections
Completed milestone
Potential key milestone
Indication
2021
2022
2023
2024
2025
Treatment of Vulvovaginal Candidiasis (VVC)
Approved June 2021
Launched Sep 2021
Reduction of Incidence of Recurrent VVC
Treatment of VVC, Further Research
Life-Threatening Infections
Indication
2021
2022
2023
2024
2025
Invasive Candidiasis (IC) and/or Candidemia
Refractory Invasive Fungal Infections (Designed for LPAD eligibility)
Invasive Aspergillosis (Combination Therapy)
Data H1:23
IV Formulation
P1 Liposomal IV Completed
Clinical Development Liposomal IV Formulation
NDA Filing H1:25
FDA Decision H2:25
Our Science
Learn more about our commitment to protecting the world against dangerous and difficult-to-treat infectious diseases.
Learn MoreOur data on invasive infections
SCYNEXIS regularly presents key infectious disease study data at top medical meetings.
Learn More